Last reviewed · How we verify
GLPG1690 film-coated tablets
GLPG1690 film-coated tablets is a Small molecule drug developed by Galapagos NV. It is currently in Phase 1 development.
GLPG1690 film-coated tablets are being studied in clinical trials for the treatment of Idiopathic Pulmonary Fibrosis and Systemic Sclerosis. The exact mechanism of GLPG1690 is unknown, but it is being tested in combination with standard treatments for these conditions.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | GLPG1690 film-coated tablets |
|---|---|
| Sponsor | Galapagos NV |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care (PHASE3)
- A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care (PHASE3)
- A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis (PHASE2)
- A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis (PHASE2)
- A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Given by Mouth and Into a Vein as an Injection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLPG1690 film-coated tablets CI brief — competitive landscape report
- GLPG1690 film-coated tablets updates RSS · CI watch RSS
- Galapagos NV portfolio CI
Frequently asked questions about GLPG1690 film-coated tablets
What is GLPG1690 film-coated tablets?
Who makes GLPG1690 film-coated tablets?
What development phase is GLPG1690 film-coated tablets in?
Related
- Manufacturer: Galapagos NV — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing